In HTA-driven environments, stability in reimbursement positioning often reflects persistence of structural constraints rather than absence of progress. Following a structured surveillance reassessment, the MARA Rating for baxdrostat in treatment-resistant
1. Executive Summary During April 2026, MARA issued 12 rating actions across multiple therapeutic areas. The monthly distribution was concentrated in B+ (Very Weak) and B++ (Marginal), with no A-range,
Link to the latest MARA Rating Executive SummaryThe MARA Rating for Leqembi (lecanemab) in early Alzheimer’s disease has been affirmed at B++ (Marginal) as of March 2026 following structured committee review. The rating band
Link to the full report here 1. Executive Summary MARA Rating has completed a formal surveillance review of CagriSema (cagrilintide + semaglutide) following publication of Phase 3 head-to-head results versus
Lecanemab — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for early Alzheimer’s disease. The complimentary MARA Rating® report evaluates Lecanemab’s market access prospects for the treatment of
Donanemab — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for Alzheimer’s disease. Donanemab has been evaluated under the MARA Rating framework for its role in slowing cognitive
Aficamten — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for hypertrophic cardiomyopathy. This complimentary MARA Rating® report evaluates Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy
Datopotamab deruxtecan — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for metastatic breast cancer. Datopotamab deruxtecan has been assessed using the MARA Rating framework for its role
Ensifentrine – complimentary MARA Rating report: pricing & reimbursement risk assessment for COPD maintenance therapy. Ensifentrine, marketed as Ohtuvayre, has been reviewed under the MARA Rating system. This assessed its
Nipocalimab – complimentary MARA Rating report: pricing & reimbursement risk assessment for generalized myasthenia gravis. This MARA Rating® complimentary report provides a market-access risk assessment of Nipocalimab for the treatment